1. Home
  2. GLPG vs BATRK Comparison

GLPG vs BATRK Comparison

Compare GLPG & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$34.53

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Logo Atlanta Braves Holdings Inc. Series C

BATRK

Atlanta Braves Holdings Inc. Series C

HOLD

Current Price

$43.45

Market Cap

2.5B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
BATRK
Founded
1999
1991
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GLPG
BATRK
Price
$34.53
$43.45
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$31.33
$58.00
AVG Volume (30 Days)
98.5K
348.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.76
$12.40
Revenue Next Year
$0.49
$6.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.59
$35.46
52 Week High
$37.78
$47.18

Technical Indicators

Market Signals
Indicator
GLPG
BATRK
Relative Strength Index (RSI) 59.21 76.63
Support Level $33.39 $38.79
Resistance Level $34.22 $40.11
Average True Range (ATR) 0.62 0.94
MACD -0.04 0.41
Stochastic Oscillator 79.83 87.25

Price Performance

Historical Comparison
GLPG
BATRK

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: